Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Earnings
Beam Therapeutics reports Q2 EPS ($1.02), consensus ($1.08) » 06:36
08/09/22
08/09
06:36
08/09/22
06:36
BEAM

Beam Therapeutics

$63.74 /

+0.4 (+0.63%)

Reports Q2 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
BEAM Beam Therapeutics
$63.74 /

+0.4 (+0.63%)

BEAM Beam Therapeutics
$63.74 /

+0.4 (+0.63%)

07/18/22 BMO Capital
Beam Therapeutics price target raised to $61 from $41 at BMO Capital
06/16/22 BMO Capital
Beam Therapeutics initiated with a Market Perform at BMO Capital
04/28/22 Credit Suisse
Beam Therapeutics initiated with a Neutral at Credit Suisse
01/10/22 Wedbush
Beam Therapeutics price target raised to $159 from $148 at Wedbush
BEAM Beam Therapeutics
$63.74 /

+0.4 (+0.63%)

BEAM Beam Therapeutics
$63.74 /

+0.4 (+0.63%)

Over a week ago
Hot Stocks
Beam Therapeutics drops 12% to $54.99 after FDA places hold on BEAM-201 IND  07:21
08/01/22
08/01
07:21
08/01/22
07:21
BEAM

Beam Therapeutics

$62.96 /

-2.635 (-4.02%)

 
ShowHide Related Items >><<
BEAM Beam Therapeutics
$62.96 /

-2.635 (-4.02%)

BEAM Beam Therapeutics
$62.96 /

-2.635 (-4.02%)

07/18/22 BMO Capital
Beam Therapeutics price target raised to $61 from $41 at BMO Capital
06/16/22 BMO Capital
Beam Therapeutics initiated with a Market Perform at BMO Capital
04/28/22 Credit Suisse
Beam Therapeutics initiated with a Neutral at Credit Suisse
01/10/22 Wedbush
Beam Therapeutics price target raised to $159 from $148 at Wedbush
BEAM Beam Therapeutics
$62.96 /

-2.635 (-4.02%)

BEAM Beam Therapeutics
$62.96 /

-2.635 (-4.02%)

Hot Stocks
Beam Therapeutics announces FDA clinical hold on BEAM-201 IND application » 06:31
08/01/22
08/01
06:31
08/01/22
06:31
BEAM

Beam Therapeutics

$62.96 /

-2.635 (-4.02%)

Beam Therapeutics…

Beam Therapeutics announced that on Friday, July 29, the company was informed via e-mail communication from the U.S. FDA that the BEAM-201 Investigational New Drug application for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma has been placed on clinical hold. BEAM-201 is a potent and specific anti-CD7, multiplex-edited, allogeneic chimeric antigen receptor T cell development candidate. The BEAM-201 IND was submitted at the end of June. The FDA indicated they will provide an official clinical hold letter to Beam within 30 days. Beam plans to provide additional updates pending discussion with the FDA.

ShowHide Related Items >><<
BEAM Beam Therapeutics
$62.96 /

-2.635 (-4.02%)

BEAM Beam Therapeutics
$62.96 /

-2.635 (-4.02%)

07/18/22 BMO Capital
Beam Therapeutics price target raised to $61 from $41 at BMO Capital
06/16/22 BMO Capital
Beam Therapeutics initiated with a Market Perform at BMO Capital
04/28/22 Credit Suisse
Beam Therapeutics initiated with a Neutral at Credit Suisse
01/10/22 Wedbush
Beam Therapeutics price target raised to $159 from $148 at Wedbush
BEAM Beam Therapeutics
$62.96 /

-2.635 (-4.02%)

BEAM Beam Therapeutics
$62.96 /

-2.635 (-4.02%)

On The Fly
Short Report: Revlon shorts recede, stock retreats as buyout news fades » 11:44
07/23/22
07/23
11:44
07/23/22
11:44
BEAM

Beam Therapeutics

$62.87 /

-5.62 (-8.21%)

, GOSS

Gossamer Bio

$11.85 /

-0.155 (-1.29%)

, GOEV

Canoo

$3.84 /

-0.205 (-5.07%)

, WMT

Walmart

$132.20 /

-0.29 (-0.22%)

, BBBY

Bed Bath & Beyond

$5.09 /

-0.74 (-12.69%)

, REV

Revlon

$5.42 /

-0.245 (-4.33%)

, VERV

Verve Therapeutics

$30.58 /

-2.195 (-6.70%)

Welcome to this week’s…

ShowHide Related Items >><<
WMT Walmart
$132.20 /

-0.29 (-0.22%)

VERV Verve Therapeutics
$30.58 /

-2.195 (-6.70%)

REV Revlon
$5.42 /

-0.245 (-4.33%)

GOSS Gossamer Bio
$11.85 /

-0.155 (-1.29%)

GOEV Canoo
$3.84 /

-0.205 (-5.07%)

BEAM Beam Therapeutics
$62.87 /

-5.62 (-8.21%)

BBBY Bed Bath & Beyond
$5.09 /

-0.74 (-12.69%)

BEAM Beam Therapeutics
$62.87 /

-5.62 (-8.21%)

07/18/22 BMO Capital
Beam Therapeutics price target raised to $61 from $41 at BMO Capital
06/16/22 BMO Capital
Beam Therapeutics initiated with a Market Perform at BMO Capital
04/28/22 Credit Suisse
Beam Therapeutics initiated with a Neutral at Credit Suisse
01/10/22 Wedbush
Beam Therapeutics price target raised to $159 from $148 at Wedbush
GOSS Gossamer Bio
$11.85 /

-0.155 (-1.29%)

07/13/22 Piper Sandler
Gossamer private placement with 'strong investors' raises Piper's conviction
04/26/22 Barclays
Gossamer Bio price target lowered to $12 from $18 at Barclays
04/26/22 H.C. Wainwright
Gossamer Bio price target lowered to $20 from $25 at H.C. Wainwright
04/25/22 Piper Sandler
Gossamer Bio price target lowered to $15 from $26 at Piper Sandler
GOEV Canoo
$3.84 /

-0.205 (-5.07%)

07/14/22 R.F. Lafferty
Canoo price target lowered to $17 from $20 at R.F. Lafferty
07/13/22 H.C. Wainwright
Canoo price target lowered to $10 from $15 at H.C. Wainwright
12/16/21 R.F. Lafferty
Canoo price target raised to $21 from $19 at R.F. Lafferty
12/16/21 Roth Capital
Roth Capital upgrades Canoo to Buy, raises price target to $14
WMT Walmart
$132.20 /

-0.29 (-0.22%)

07/22/22 Piper Sandler
Walmart initiated with a Neutral at Piper Sandler
07/13/22 Evercore ISI
Evercore downgrades Hanesbrands on reversion in consumer spending
07/07/22 Oppenheimer
Walmart removed as a Top Pick at Oppenheimer
06/27/22 Goldman Sachs
Walmart price target lowered to $138 from $160 at Goldman Sachs
BBBY Bed Bath & Beyond
$5.09 /

-0.74 (-12.69%)

06/30/22 B. Riley
Bed Bath & Beyond price target lowered to $5 from $7 at B. Riley
06/30/22 Baird
Bed Bath & Beyond price target lowered to $4 from $7 at Baird
06/30/22 Loop Capital
Bed Bath & Beyond price target lowered to $1 from $5 at Loop Capital
06/30/22 Morgan Stanley
Bed Bath & Beyond price target lowered to $2 from $7 at Morgan Stanley
REV Revlon
$5.42 /

-0.245 (-4.33%)

VERV Verve Therapeutics
$30.58 /

-2.195 (-6.70%)

07/18/22 BMO Capital
Verve Therapeutics price target raised to $62 from $48 at BMO Capital
06/16/22 BMO Capital
Verve Therapeutics initiated with an Outperform at BMO Capital
03/14/22 Stifel
Verve Therapeutics price target lowered to $34 from $58 at Stifel
02/17/22 RBC Capital
RBC Capital starts Verve Therapeutics at Outperform on 'disruptive' treatment
WMT Walmart
$132.20 /

-0.29 (-0.22%)

VERV Verve Therapeutics
$30.58 /

-2.195 (-6.70%)

REV Revlon
$5.42 /

-0.245 (-4.33%)

GOSS Gossamer Bio
$11.85 /

-0.155 (-1.29%)

GOEV Canoo
$3.84 /

-0.205 (-5.07%)

BEAM Beam Therapeutics
$62.87 /

-5.62 (-8.21%)

BBBY Bed Bath & Beyond
$5.09 /

-0.74 (-12.69%)

  • 21
    Jul
WMT Walmart
$132.20 /

-0.29 (-0.22%)

REV Revlon
$5.42 /

-0.245 (-4.33%)

GOEV Canoo
$3.84 /

-0.205 (-5.07%)

BBBY Bed Bath & Beyond
$5.09 /

-0.74 (-12.69%)

WMT Walmart
$132.20 /

-0.29 (-0.22%)

VERV Verve Therapeutics
$30.58 /

-2.195 (-6.70%)

REV Revlon
$5.42 /

-0.245 (-4.33%)

GOSS Gossamer Bio
$11.85 /

-0.155 (-1.29%)

GOEV Canoo
$3.84 /

-0.205 (-5.07%)

BEAM Beam Therapeutics
$62.87 /

-5.62 (-8.21%)

BBBY Bed Bath & Beyond
$5.09 /

-0.74 (-12.69%)

WMT Walmart
$132.20 /

-0.29 (-0.22%)

REV Revlon
$5.42 /

-0.245 (-4.33%)

GOEV Canoo
$3.84 /

-0.205 (-5.07%)

BBBY Bed Bath & Beyond
$5.09 /

-0.74 (-12.69%)

Recommendations
Beam Therapeutics price target raised to $61 from $41 at BMO Capital » 09:34
07/18/22
07/18
09:34
07/18/22
09:34
BEAM

Beam Therapeutics

$57.61 /

+1.445 (+2.57%)

BMO Capital analyst…

BMO Capital analyst Kostas Biliouris raised the firm's price target on Beam Therapeutics to $61 from $41 but keeps a Market Perform rating on the shares. The analyst is positive on the company's recent advancements as Verve - one of the major Beam's partners - is applying Beam's base editing technology in the cardiovascular disease space. Biliouris adds however that while he is keen on the "great potential" of the Beam platform, all of its assets are "early" and clinical derisking "has not been established".

ShowHide Related Items >><<
BEAM Beam Therapeutics
$57.61 /

+1.445 (+2.57%)

BEAM Beam Therapeutics
$57.61 /

+1.445 (+2.57%)

06/16/22 BMO Capital
Beam Therapeutics initiated with a Market Perform at BMO Capital
04/28/22 Credit Suisse
Beam Therapeutics initiated with a Neutral at Credit Suisse
01/10/22 Wedbush
Beam Therapeutics price target raised to $159 from $148 at Wedbush
01/05/22 Guggenheim
Guggenheim starts Beam Therapeutics with a Buy rating, $130 price target
BEAM Beam Therapeutics
$57.61 /

+1.445 (+2.57%)

BEAM Beam Therapeutics
$57.61 /

+1.445 (+2.57%)

Over a month ago
Hot Stocks
Beam Therapeutics to present new research at FASEB conference » 06:34
06/27/22
06/27
06:34
06/27/22
06:34
BEAM

Beam Therapeutics

$42.55 /

+0.985 (+2.37%)

Beam Therapeutics…

Beam Therapeutics announced that new research highlighting the company's internal efforts to develop improved transplant conditioning regimens for patients with sickle cell disease undergoing hematopoietic stem cell transplantation will be presented today, June 27, 2022, at 4:00 p.m. CEST at the Federation of American Societies for Experimental Biology Genome Engineering Conference by Nicole Gaudelli, Ph.D., director, head of gene editing at Beam. The conference is being held from June 26-30, 2022, in Lisbon, Portugal. New antibody-based conditioning agents have shown promise in targeting CD117, an optimal conditioning target for eliminating HSCs, but such antibodies generally cannot discriminate between host and transplanted cells, and therefore are designed with short half-life or dosed at low concentrations well before transplant. To potentially solve for this and other safety concerns associated with current conditioning regimens, Beam scientists developed ESCAPE, whereby an edit-antibody pair targeting CD117 was designed to enable edited HSCs to function normally but escape the binding of the conditioning antibody. This strategy is intended to allow the conditioning antibody to continue clearing older unedited host cells while selectively allowing new edited cells to proliferate in the body during engraftment. The findings show that in vitro the ESCAPE antibodies bound to wild-type CD117, blocked binding of its ligand and led to depletion of unedited cells, while enriching for edited cells which were generally not bound by the antibody. High levels of editing efficiency were demonstrated with both a single CD117 edit and simultaneous CD117 and BEAM-101 edits. Beam has also developed a CD117 editing strategy with greater than 75% editing efficiency that is also compatible with an edit to correct the sickle mutation and generate HbG-Makassar, Beam's strategy with its BEAM-102 program. Relative to a control, ESCAPE reduced cell viability of unedited cells while maintaining CD117 edited cells in vitro, suggesting utility as a conditioning agent with a selective advantage to edited HSCs post-transplant.

ShowHide Related Items >><<
BEAM Beam Therapeutics
$42.55 /

+0.985 (+2.37%)

BEAM Beam Therapeutics
$42.55 /

+0.985 (+2.37%)

06/16/22 BMO Capital
Beam Therapeutics initiated with a Market Perform at BMO Capital
04/28/22 Credit Suisse
Beam Therapeutics initiated with a Neutral at Credit Suisse
01/10/22 Wedbush
Beam Therapeutics price target raised to $159 from $148 at Wedbush
01/05/22 Guggenheim
Guggenheim starts Beam Therapeutics with a Buy rating, $130 price target
BEAM Beam Therapeutics
$42.55 /

+0.985 (+2.37%)

BEAM Beam Therapeutics
$42.55 /

+0.985 (+2.37%)

Initiation
Beam Therapeutics initiated with a Market Perform at BMO Capital » 16:24
06/16/22
06/16
16:24
06/16/22
16:24
BEAM

Beam Therapeutics

$32.24 /

+0.32 (+1.00%)

BMO Capital analyst…

BMO Capital analyst Kostas Biliouris initiated coverage of Beam Therapeutics with a Market Perform rating and $41 price target. The analyst appreciates the "high potential" of Beam's next-generation editing approach, but thinks the stock's current risk/reward already assumes clinical success.

ShowHide Related Items >><<
BEAM Beam Therapeutics
$32.24 /

+0.32 (+1.00%)

BEAM Beam Therapeutics
$32.24 /

+0.32 (+1.00%)

04/28/22 Credit Suisse
Beam Therapeutics initiated with a Neutral at Credit Suisse
01/10/22 Wedbush
Beam Therapeutics price target raised to $159 from $148 at Wedbush
01/05/22 Guggenheim
Guggenheim starts Beam Therapeutics with a Buy rating, $130 price target
01/05/22 Guggenheim
Beam Therapeutics initiated with a Buy at Guggenheim
BEAM Beam Therapeutics
$32.24 /

+0.32 (+1.00%)

BEAM Beam Therapeutics
$32.24 /

+0.32 (+1.00%)

On The Fly
Proven algorithm says sell these stocks now » 13:59
05/20/22
05/20
13:59
05/20/22
13:59
SOFI

SoFi Technologies

$7.27 /

-0.47 (-6.07%)

, CGC

Canopy Growth

$5.47 /

-0.4 (-6.81%)

, FRPT

Freshpet

$60.33 /

-6.02 (-9.07%)

, BEAM

Beam Therapeutics

$32.45 /

-1.5 (-4.42%)

, SST

System1

$10.32 /

-0.625 (-5.71%)

, AI

C3.ai

$17.67 /

-0.36 (-2.00%)

, KRYS

Krystal Biotech

$56.75 /

-0.03 (-0.05%)

, ASTS

AST SpaceMobile

$7.21 /

+0.11 (+1.55%)

, RSI

Rush Street Interactive

$6.00 /

-0.04 (-0.66%)

, MSTR

MicroStrategy

$194.98 /

-15.34 (-7.29%)

, SG

Sweetgreen

$20.15 /

-1.98 (-8.95%)

, ARRY

Array Technologies

$8.93 /

-0.085 (-0.94%)

, CYXT

Cyxtera Technologies

$12.50 /

-0.32 (-2.50%)

, GDS

GDS Holdings

$27.89 /

-3.21 (-10.32%)

, RKLB

Rocket Lab

$4.60 /

-0.13 (-2.75%)

, SA

Seabridge Gold

$14.17 /

-0.41 (-2.81%)

Each week, The Fly will…

ShowHide Related Items >><<
SST System1
$10.32 /

-0.625 (-5.71%)

SOFI SoFi Technologies
$7.27 /

-0.47 (-6.07%)

SG Sweetgreen
$20.15 /

-1.98 (-8.95%)

RSI Rush Street Interactive
$6.00 /

-0.04 (-0.66%)

RKLB Rocket Lab
$4.60 /

-0.13 (-2.75%)

MSTR MicroStrategy
$194.98 /

-15.34 (-7.29%)

KRYS Krystal Biotech
$56.75 /

-0.03 (-0.05%)

GDS GDS Holdings
$27.89 /

-3.21 (-10.32%)

FRPT Freshpet
$60.33 /

-6.02 (-9.07%)

CYXT Cyxtera Technologies
$12.50 /

-0.32 (-2.50%)

CGC Canopy Growth
$5.47 /

-0.4 (-6.81%)

BEAM Beam Therapeutics
$32.45 /

-1.5 (-4.42%)

ASTS AST SpaceMobile
$7.21 /

+0.11 (+1.55%)

ARRY Array Technologies
$8.93 /

-0.085 (-0.94%)

AI C3.ai
$17.67 /

-0.36 (-2.00%)

SOFI SoFi Technologies
$7.27 /

-0.47 (-6.07%)

05/17/22 Mizuho
SoFi Technologies price target lowered to $9 from $14 at Mizuho
05/16/22 Piper Sandler
Piper upgrades SoFi to buy ahead of 'significant' earnings ramp
05/16/22 Piper Sandler
SoFi Technologies upgraded to Overweight from Neutral at Piper Sandler
05/12/22 Citi
SoFi Technologies price target lowered to $11 from $17 at Citi
CGC Canopy Growth
$5.47 /

-0.4 (-6.81%)

05/20/22 Alliance Global Partners
Canopy Growth price target lowered to C$8 from C$11 at Alliance Global Partners
04/04/22 Morgan Stanley
Constellation Brands price target lowered to $294 from $299 at Morgan Stanley
04/01/22 Alliance Global Partners
Senate remains the hurdle for MORE Act, says Alliance Global Partners
03/22/22 Barclays
Canopy Growth downgraded to Underweight from Equal Weight at Barclays
FRPT Freshpet
$60.33 /

-6.02 (-9.07%)

05/20/22 Atlantic Equities
Atlantic Equities sees more volatility for Freshpet, downgrades shares
05/20/22 Atlantic Equities
Freshpet downgraded to Neutral from Overweight at Atlantic Equities
05/03/22 Cowen
Freshpet price target lowered to $163 from $181 at Cowen
05/03/22 Oppenheimer
Freshpet price target lowered to $110 from $120 at Oppenheimer
BEAM Beam Therapeutics
$32.45 /

-1.5 (-4.42%)

04/28/22 Credit Suisse
Beam Therapeutics initiated with a Neutral at Credit Suisse
01/10/22 Wedbush
Beam Therapeutics price target raised to $159 from $148 at Wedbush
01/05/22 Guggenheim
Guggenheim starts Beam Therapeutics with a Buy rating, $130 price target
01/05/22 Guggenheim
Beam Therapeutics initiated with a Buy at Guggenheim
SST System1
$10.32 /

-0.625 (-5.71%)

04/26/22 Evercore ISI
System1 initiated with an In Line at Evercore ISI
04/06/22 DA Davidson
System1 price target raised to $26 from $23 at DA Davidson
04/06/22 Benchmark
System1 'more than a meme,' but trading likely to stay volatile, says Benchmark
11/29/21 DA Davidson
Trebia Acquisition initiated with a Buy at DA Davidson
AI C3.ai
$17.67 /

-0.36 (-2.00%)

05/03/22 Wedbush
Wedbush downgrades C3.ai to Neutral, lowers price target to $16
05/03/22 Wedbush
C3.ai downgraded to Neutral from Outperform at Wedbush
03/25/22 Morgan Stanley
C3.ai price target lowered to $20 from $31 at Morgan Stanley
03/04/22 Deutsche Bank
Deutsche downgrades C3.ai to Sell, says 'all is not well'
KRYS Krystal Biotech
$56.75 /

-0.03 (-0.05%)

03/29/22 Guggenheim
Krystal Biotech price target lowered to $101 from $114 at Guggenheim
02/28/22 H.C. Wainwright
Krystal Biotech price target lowered to $107 from $124 at H.C. Wainwright
01/18/22 BofA
Krystal Biotech initiated with a Buy at BofA
01/18/22 BofA
Krystal Biotech initiated with a Buy at BofA
ASTS AST SpaceMobile
$7.21 /

+0.11 (+1.55%)

04/01/22 Deutsche Bank
AST SpaceMobile price target lowered to $32 from $35 at Deutsche Bank
07/12/21 Barclays
AST SpaceMobile initiated with an Overweight at Barclays
06/30/21 Deutsche Bank
AST SpaceMobile initiated with a Buy at Deutsche Bank
RSI Rush Street Interactive
$6.00 /

-0.04 (-0.66%)

04/27/22 Wells Fargo
Wells Fargo upgrades Rush Street Interactive to Overweight, lowers target to $10
04/27/22 Wells Fargo
Rush Street upgraded to Overweight from Equal Weight at Wells Fargo
03/10/22 Benchmark
Rush Street Interactive price target lowered to $16 from $27 at Benchmark
03/03/22 Oppenheimer
Rush Street Interactive price target lowered to $11 from $14 at Oppenheimer
MSTR MicroStrategy
$194.98 /

-15.34 (-7.29%)

05/16/22 Jefferies
MicroStrategy does not face liquidity, solvency risk, says Jefferies
05/13/22 William Blair
MicroStrategy can 'comfortably' support interest payments, says William Blair
05/04/22 Canaccord
MicroStrategy price target lowered to $453 from $540 at Canaccord
02/02/22 Canaccord
MicroStrategy price target lowered to $540 from $871 at Canaccord
SG Sweetgreen
$20.15 /

-1.98 (-8.95%)

04/12/22 Citi
Sweetgreen initiated with a Neutral at Citi
03/17/22 Cowen
Cowen favors domestic restaurant chains as inflation hurts sector
03/04/22 Morgan Stanley
Morgan Stanley says first post-IPO report a positive for Sweetgreen shares
03/04/22 Oppenheimer
Sweetgreen price target lowered to $37 from $41 at Oppenheimer
ARRY Array Technologies
$8.93 /

-0.085 (-0.94%)

05/12/22 Truist
Array Technologies price target lowered to $8 from $14 at Truist
05/11/22 Roth Capital
Array Technologies downgraded to Neutral from Buy at Roth Capital
05/02/22 Truist
Array Technologies assumed with a Hold at Truist
04/21/22 Piper Sandler
Array Technologies price target lowered to $12 from $16 at Piper Sandler
CYXT Cyxtera Technologies
$12.50 /

-0.32 (-2.50%)

04/07/22 Cowen
Cyxtera Technologies lack of asset ownership limits valuation, says Cowen
04/07/22 Credit Suisse
Cyxtera Technologies initiated with an Outperform at Credit Suisse
01/28/22 William Blair
Cyxtera Technologies initiated with an Outperform at William Blair
01/06/22 Cowen
Cyxtera Technologies initiated with an Outperform at Cowen
GDS GDS Holdings
$27.89 /

-3.21 (-10.32%)

05/19/22 Truist
GDS Holdings price target lowered to $75 from $85 at Truist
05/19/22 Cowen
GDS Holdings price target lowered to $47 from $53 at Cowen
05/19/22 Raymond James
GDS Holdings price target lowered to $55 from $68 at Raymond James
05/16/22 Credit Suisse
GDS Holdings price target lowered to $48.90 from $71.50 at Credit Suisse
RKLB Rocket Lab
$4.60 /

-0.13 (-2.75%)

05/17/22 Canaccord
Rocket Lab price target lowered to $16 from $28 at Canaccord
05/17/22 Deutsche Bank
Rocket Lab price target lowered to $14 from $18 at Deutsche Bank
02/23/22 Roth Capital
Rocket Lab initiated with a Buy at Roth Capital
01/28/22 Deutsche Bank
Rocket Lab most promising rocket company after SpaceX, says Deutsche Bank
SA Seabridge Gold
$14.17 /

-0.41 (-2.81%)

SST System1
$10.32 /

-0.625 (-5.71%)

SOFI SoFi Technologies
$7.27 /

-0.47 (-6.07%)

SG Sweetgreen
$20.15 /

-1.98 (-8.95%)

RSI Rush Street Interactive
$6.00 /

-0.04 (-0.66%)

RKLB Rocket Lab
$4.60 /

-0.13 (-2.75%)

MSTR MicroStrategy
$194.98 /

-15.34 (-7.29%)

KRYS Krystal Biotech
$56.75 /

-0.03 (-0.05%)

GDS GDS Holdings
$27.89 /

-3.21 (-10.32%)

FRPT Freshpet
$60.33 /

-6.02 (-9.07%)

CYXT Cyxtera Technologies
$12.50 /

-0.32 (-2.50%)

CGC Canopy Growth
$5.47 /

-0.4 (-6.81%)

BEAM Beam Therapeutics
$32.45 /

-1.5 (-4.42%)

ARRY Array Technologies
$8.93 /

-0.085 (-0.94%)

AI C3.ai
$17.67 /

-0.36 (-2.00%)

  • 04
    May
  • 01
    Dec
  • 16
    Nov
  • 18
    Nov
  • 10
    Nov
SOFI SoFi Technologies
$7.27 /

-0.47 (-6.07%)

SG Sweetgreen
$20.15 /

-1.98 (-8.95%)

RSI Rush Street Interactive
$6.00 /

-0.04 (-0.66%)

MSTR MicroStrategy
$194.98 /

-15.34 (-7.29%)

GDS GDS Holdings
$27.89 /

-3.21 (-10.32%)

CYXT Cyxtera Technologies
$12.50 /

-0.32 (-2.50%)

CGC Canopy Growth
$5.47 /

-0.4 (-6.81%)

ARRY Array Technologies
$8.93 /

-0.085 (-0.94%)

AI C3.ai
$17.67 /

-0.36 (-2.00%)

SST System1
$10.32 /

-0.625 (-5.71%)

SOFI SoFi Technologies
$7.27 /

-0.47 (-6.07%)

SG Sweetgreen
$20.15 /

-1.98 (-8.95%)

RSI Rush Street Interactive
$6.00 /

-0.04 (-0.66%)

RKLB Rocket Lab
$4.60 /

-0.13 (-2.75%)

MSTR MicroStrategy
$194.98 /

-15.34 (-7.29%)

KRYS Krystal Biotech
$56.75 /

-0.03 (-0.05%)

GDS GDS Holdings
$27.89 /

-3.21 (-10.32%)

FRPT Freshpet
$60.33 /

-6.02 (-9.07%)

CYXT Cyxtera Technologies
$12.50 /

-0.32 (-2.50%)

CGC Canopy Growth
$5.47 /

-0.4 (-6.81%)

BEAM Beam Therapeutics
$32.45 /

-1.5 (-4.42%)

ASTS AST SpaceMobile
$7.21 /

+0.11 (+1.55%)

ARRY Array Technologies
$8.93 /

-0.085 (-0.94%)

AI C3.ai
$17.67 /

-0.36 (-2.00%)

SST System1
$10.32 /

-0.625 (-5.71%)

SOFI SoFi Technologies
$7.27 /

-0.47 (-6.07%)

SG Sweetgreen
$20.15 /

-1.98 (-8.95%)

SA Seabridge Gold
$14.17 /

-0.41 (-2.81%)

RKLB Rocket Lab
$4.60 /

-0.13 (-2.75%)

MSTR MicroStrategy
$194.98 /

-15.34 (-7.29%)

GDS GDS Holdings
$27.89 /

-3.21 (-10.32%)

CGC Canopy Growth
$5.47 /

-0.4 (-6.81%)

ASTS AST SpaceMobile
$7.21 /

+0.11 (+1.55%)

ARRY Array Technologies
$8.93 /

-0.085 (-0.94%)

AI C3.ai
$17.67 /

-0.36 (-2.00%)

Over a quarter ago
Earnings
Beam Therapeutics reports Q1 EPS ($1.01), consensus ($1.32) » 06:43
05/09/22
05/09
06:43
05/09/22
06:43
BEAM

Beam Therapeutics

$35.68 /

-1.26 (-3.41%)

Reports Q1 revenue…

Reports Q1 revenue $8.43M, consensus $5.91M. "Base editing has the potential to offer life-changing medicines for a broad range of diseases, and we are committed to better understanding the pathophysiology of the diseases in our pipeline, and their impacts on the lives of patients and their families," said CEO John Evans. "We are excited to be collaborating with the Globin Research Network for Data and Discovery on the AUNT natural history study in people with sickle cell trait. We are on track and expect to commence SCD patient enrollment in our Phase 1/2 BEACON-101 clinical trial to evaluate the safety and efficacy of BEAM-101 in patients with SCD, as well as make our planned IND submission for BEAM-102, which is also in development for the treatment of SCD. Our immunology and liver-directed pipelines are also progressing, with plans for additional regulatory submissions, research studies and program nominations throughout the year, and we continue to build upon our delivery capabilities, including our novel LNP technology platform, potentially allowing us to expand the future reach of our programs. We believe the parallel advancement of these diverse programs creates a broad foundation for our future growth and is evidence of our commitment to developing new and better treatments for multiple patient populations and to unlocking the full potential of precision genetic medicine."

ShowHide Related Items >><<
BEAM Beam Therapeutics
$35.68 /

-1.26 (-3.41%)

BEAM Beam Therapeutics
$35.68 /

-1.26 (-3.41%)

04/28/22 Credit Suisse
Beam Therapeutics initiated with a Neutral at Credit Suisse
01/10/22 Wedbush
Beam Therapeutics price target raised to $159 from $148 at Wedbush
01/05/22 Guggenheim
Guggenheim starts Beam Therapeutics with a Buy rating, $130 price target
01/05/22 Guggenheim
Beam Therapeutics initiated with a Buy at Guggenheim
BEAM Beam Therapeutics
$35.68 /

-1.26 (-3.41%)

BEAM Beam Therapeutics
$35.68 /

-1.26 (-3.41%)

Initiation
Beam Therapeutics initiated with a Neutral at Credit Suisse » 07:05
04/28/22
04/28
07:05
04/28/22
07:05
BEAM

Beam Therapeutics

$39.81 /

-0.36 (-0.90%)

, CRSP

Crispr Therapeutics

$51.98 /

-0.9 (-1.70%)

Credit Suisse analyst…

Credit Suisse analyst Richard Law initiated coverage of Beam Therapeutics (BEAM) with a Neutral rating and $62 price target. The company's lead programs, and "main value drivers," are BEAM-101/102 in sickle cell disease, or SCD, said Law. Competition, such as Crispr Therapeutics' (CRSP) CTX001, has already demonstrated curative potential in freeing SCD patients from vaso-occlusive episodes so he is "not sure what additional value BEAM can bring," said Law, who sees Beam being multiple years behind the competition.

ShowHide Related Items >><<
CRSP Crispr Therapeutics
$51.98 /

-0.9 (-1.70%)

BEAM Beam Therapeutics
$39.81 /

-0.36 (-0.90%)

BEAM Beam Therapeutics
$39.81 /

-0.36 (-0.90%)

01/10/22 Wedbush
Beam Therapeutics price target raised to $159 from $148 at Wedbush
01/05/22 Guggenheim
Guggenheim starts Beam Therapeutics with a Buy rating, $130 price target
01/05/22 Guggenheim
Beam Therapeutics initiated with a Buy at Guggenheim
10/19/21 SVB Securities
Beam Therapeutics initiated with an Outperform at SVB Leerink
CRSP Crispr Therapeutics
$51.98 /

-0.9 (-1.70%)

03/15/22 Citi
Crispr Therapeutics price target lowered to $64 from $90 at Citi
02/16/22 Stifel
Stifel cuts Crispr price target to $64, says valuation 'becoming interesting'
02/16/22 RBC Capital
Crispr Therapeutics price target lowered to $95 from $117 at RBC Capital
02/16/22 SVB Securities
Crispr Therapeutics price target raised to $126 from $120 at SVB Leerink
CRSP Crispr Therapeutics
$51.98 /

-0.9 (-1.70%)

BEAM Beam Therapeutics
$39.81 /

-0.36 (-0.90%)

BEAM Beam Therapeutics
$39.81 /

-0.36 (-0.90%)

CRSP Crispr Therapeutics
$51.98 /

-0.9 (-1.70%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.